MARKET

MTNB

MTNB

Matinas
AMEX

Real-time Quotes | Nasdaq Last Sale

1.040
+0.140
+15.56%
After Hours: 1.060 +0.02 +1.92% 19:51 11/15 EST
OPEN
1.100
PREV CLOSE
0.9000
HIGH
1.100
LOW
0.9802
VOLUME
4.47M
TURNOVER
--
52 WEEK HIGH
1.500
52 WEEK LOW
0.5010
MARKET CAP
168.92M
P/E (TTM)
-7.8967
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MTNB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MTNB News

  • Mid-Morning Market Update: Markets Open Higher; JC Penney Reports Narrower-Than-Expected Q3 Loss
  • Benzinga.11h ago
  • Amarin Stock Is Rising After Favorable Vote on Fish-Based Heart Drug
  • Barrons.com.13h ago
  • Amarin shares rise in premarket trading on FDA adcom vote for new label
  • MarketWatch.13h ago
  • Acasti & Matinas perk up on positive Ad Com vote for Amarin's Vascepa
  • seekingalpha.22h ago

More

Industry

Biotechnology & Medical Research
+1.35%
Pharmaceuticals & Medical Research
+1.27%

Hot Stocks

Name
Price
%Change

About MTNB

Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
More

Webull offers Matinas BioPharma Holdings Inc (MTNB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.